Agilent Technologies presents Thought Leader Award to renowned medicinal scientist in China
Dr Shilin Chen Recognized for Herbal Genomics Research.
Agilent Technologies has announced that Dr Shilin Chen has received an Agilent Thought Leader Award in support of his ground-breaking herbal genomics research using multi-omics techniques.
Dr Chen directs the Institute of Chinese Materia Medica at the China Academy of Chinese Medical Sciences in Beijing. The institute strives to identify the active ingredients in traditional Chinese medicines and make new drugs.
The award will fund the use of integrated biology — including various multi-omic solutions from Agilent — to generate important biological data sets related to the biosynthesis of bioactive compounds from herbs, including artemisinin and glycyrrhizin, for example.
Through his research, Dr Chen hopes to deepen understanding of the mechanism by which herbal medicines disrupt diseases and identify relevant biomarkers, which could then point the way to new drug discovery.
“We are delighted to receive an Agilent Thought Leader Award. It will allow us to incorporate integrated experimental and bioinformatics approaches to traditional Chinese medicine,” said Dr Chen. “Our group is focusing on dissecting and understanding the biosynthesis and regulatory mechanisms responsible for specific metabolic processes generated by natural herbs. We have initiated the herbal genomic project, and Agilent’s innovative technologies and unique solutions can provide new tools and approaches to help us combine metabolomics and genomics in the study of traditional Chinese medicine. We are looking forward to working collaboratively with Agilent scientists to accelerate the discovery and characterization of new medicines.”
“We are pleased to support Dr Chen’s efforts in the systems-level analysis of herbal metabolic processes using integrated omics approaches,” said Dr Teng Chai Hock, vice president and general manager of Agilent’s Life Sciences and Applied Markets Group in Greater China. “Dr Chen’s research is a prime example of continued innovation in traditional Chinese medicine through the application of advanced analytical methods.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance